Urinary Biomarkers of OI Pathobiology
- Conditions
- Osteogenesis Imperfecta
- Registration Number
- NCT02531087
- Lead Sponsor
- Baylor College of Medicine
- Brief Summary
Osteogenesis imperfecta (OI) is a rare inherited disorder that causes bones to break easily. Individuals with osteogenesis imperfecta break bones often and may have other problems, including hearing loss, dental problems, pain and difficulty getting around. Before the genetic cause of OI was known, OI was classified into four types. Each type was based upon the symptoms and severity of OI. In most people with OI, the cause is a change in one of the genes that makes a protein called type 1 collagen. Some doctors now classify OI both on how severe it is as well as which gene is causing OI. When people classify OI this way, there are more than 10 types of OI. The current laboratory testing to determine OI subtype involves the collection of blood and/or skin cells.
- Detailed Description
Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. OI can range from very severe to very mild. Individuals with the most severe type of OI may die at birth. People with severe OI who survive may have bowed arms and legs, very short stature and be unable to walk. People with the mildest form of OI may only break bones occasionally and have normal height and lifespan. Breaks can occur in any bone, but are most common in the arms and legs. People with OI also often have problems with the spine. The spine problems include compression fractures and scoliosis (a curvature of the spine). DI is characterized by grey or brown teeth that may chip and wear down and break easily. In addition to weak teeth, the teeth in the upper jaw may not match up with the teeth in the lower jaw.
Before the genetic cause of OI was known, OI was classified into four types. Each type was based upon the symptoms and severity of OI. In most people with OI, the cause is a change in one of the genes that makes a protein called type 1 collagen. In the past decade, it was discovered that in about 5% of people with OI it is in another gene. Some doctors now classify OI both on how severe it is as well as which gene is causing OI. When people classify OI this way, there are more than 10 types of OI. The current laboratory testing to determine OI subtype involves the collection of blood and/or skin cells.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 25
- To be able to participate, you must:
Be enrolled in The Longitudinal Study of OI (NTC #02432625) and have one of the following genetic mutations:
- glycine substitution mutations in COL1A1 or COL1A2
- haploinsufficient mutation in COL1A1 or COL1A2
- mutations in CRTAP, PPIB, or LEPRE1
- mutations in FKBP10 or SERPINH1
- mutations in (SERPINF1, WNT1, or IFITM5)
- dominant negative glycine substitutions and haploinsufficient mutations in COL1A1, and COL1A2
If you are serving as a control, you must not be related to an individual with OI.
- You cannot participate if:
- You are unable to comply with the sample collection schedule.
- You are related to one of the OI subjects and would like to serve as a control subject.
- You have vertebral instrumentation or spinal deformities where we cannot assess lumbar spine aBMD.
- You have a history of recent fracture (< 3 months).
- You have serum creatinine above 1x upper limits of normal.
- You have abnormal kidney function.
- You are using Minoxidil.
- You are unable to provide a urine sample readily.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HP/LP Ratio 5 Years The endpoint will be to compare the HP/LP ratio in OI patients with collagen overmodification (dominant negative mutations in COL1A1, COL1A2, and biallelic mutations in CRTAP, LEPRE1, PPIB) to those without overmodification (FKBP10, SERPINH1, IFITM5, SERPINF1, WNT1, and haploinsufficient mutations in COL1A1 and COL1A2).
- Secondary Outcome Measures
Name Time Method HP/LP ratio 5 Years The endpoint would be the HP/LP ratio in those with dominant negative type I collagen mutations vs. those with mutations in P3H complex.
Trial Locations
- Locations (6)
Shriners Hospital for Children
🇨🇦Montreal, Quebec, Canada
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Oregon Health Science University
🇺🇸Portland, Oregon, United States
University of California Los Angeles
🇺🇸Los Angeles, California, United States
Hospital for Special Surgery
🇺🇸New York, New York, United States
Baylor College of Medicine
🇺🇸Houston, Texas, United States